Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has secured “several hundreds of millions of yuan” ($14 million) in a funding round participated by local investment firm Tsing Song Capital.
Nothing here but dreams
Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has secured “several hundreds of millions of yuan” ($14 million) in a funding round participated by local investment firm Tsing Song Capital.